---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-086368"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T16:37:00.838756+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rigel Q2 net loss narrows to $6.6M; TAVALISSE sales up 15% YoY to $21.3M

## Summary
- Q2 net loss $6.6M ($0.04/sh) vs $13.5M loss in Q2 2022; total revenue $26.9M.
- TAVALISSE net product sales $21.3M (+15% YoY); REZLIDHIA sales $2.6M with 77% sequential bottle growth.
- Cash, equivalents & investments $64.4M at June 30, up from $58.2M at Dec 31, 2022.
- R289 Phase 1b in LR-MDS completed cohort 2 enrollment; R552 Phase 2a in RA initiated by Eli Lilly.

## SEC filing metadata
- accession: 0001104659-23-086368
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465923086368/0001104659-23-086368-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465923086368/tm2322488d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-086368
- JSON: https://secwatch.observer/filing/0001104659-23-086368.json
- Plain text: https://secwatch.observer/filing/0001104659-23-086368.txt

## Key facts
- Earnings Releases
  RIGEL PHARMACEUTICALS INC reported the second quarter ended June 30, 2023 results: revenue $26.9 million, net income net loss of $6.6 million, EPS $0.04 per basic and diluted share.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $26.9 million
  - Net income: net loss of $6.6 million
  - EPS: $0.04 per basic and diluted share
  - Result: reported results
  source text: For the second quarter of 2023, Rigel reported a net loss of $6.6 million, or $0.04 per basic and diluted share, compared to a net loss of $13.5 million, or $0.08 per basic and diluted share, for the same period of 2022. For the second quarter of 2023, total revenues were $26.9 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000110465923086368/0001104659-23-086368-index.htm
- Earnings Releases
  RIGEL PHARMACEUTICALS INC reported the six months ended June 30, 2023 results: revenue $52.9 million, net income net loss of $20.1 million, EPS $0.12 per basic and diluted share.
  - Period: the six months ended June 30, 2023
  - Revenue: $52.9 million
  - Net income: net loss of $20.1 million
  - EPS: $0.12 per basic and diluted share
  - Result: reported results
  source text: For the six months ended June 30, 2023, Rigel reported a net loss of $20.1 million, or $0.12 per basic and diluted share, compared to a net loss of $40.9 million, or $0.24 per basic and diluted share, for the same period of 2022. For the six months ended June 30, 2023, total revenues were $52.9 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000110465923086368/0001104659-23-086368-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.